Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

China · Delayed Price · Currency is CNY

30.41

+1.22 (4.18%)

Jun 23, 2026, 3:00 PM CST

2.81% (1Y)

Market Cap	4.79B -3.3%
Revenue (ttm)	917.99M +9.5%
Net Income	168.68M +274.4%
EPS	1.06 +270.4%
Shares Out	157.53M
PE Ratio	28.70
Forward PE	26.91
Dividend	0.35 (1.20%)
Ex-Dividend Date	Jun 9, 2025

Volume	4,118,700
Open	28.99
Previous Close	29.19
Day's Range	28.81 - 30.78
52-Week Range	27.89 - 67.98
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 793

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603590

Full Company Profile

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.

Financial Statements